葡萄球菌，鏈球菌，肺炎雙球菌，腦膜炎球菌及其他具有感受性細菌引起之感染症。

Antibiotic, Aminoglycoside

Absorption: rapid.
Distribution: primarily into extracellular fluid (highly hydrophilic); poor penetration into the blood-brain barrier even when meninges are inflamed; Adults: 0.25 L/kg.
Protein binding: 0% to 11%.
Half-life elimination: Adults: Normal renal function: ~2 hours; Anuria/end-stage renal disease: 17 to 150 hours.
Time to peak, serum: IM: 60 minutes; IV: Within 30 minutes following a 30-minute infusion.
Excretion: urine (94% to 98% unchanged).

Hypersensitivity to amikacin, other aminoglycosides, or any component of the formulation

D; Amikacin crosses the placenta.

Amikacin is present in breast milk.

Neurotoxicity (including muscle twitching, numbness, seizure, tingling of skin), auditory ototoxicity, vestibular ototoxicity, nephrotoxicity, respiratory paralysis.

1. Bloodstream infection: IV: 15 to 30 mg/kg once daily in combination with a second gram-negative active agent.
2. Cerebrospinal fluid (CSF) shunt infection (susceptible gram-negative organisms) : IV: 5 mg/kg every 8 hours in combination with other appropriate agents; Intraventricular/intrathecal: 5 to 50 mg/day; usual dose: 30 mg/day.
3. Cystic fibrosis, acute pulmonary exacerbation (off-label use) : IV: 30 to 35 mg/kg once daily in combination with other appropriate agents; adjust dose and interval to achieve a target peak of 80 to 120 mg/L and trough <1 mg/L.
4. Meningitis, bacterial (susceptible gram-negative organisms) : IV: 5 mg/kg every 8 hours in combination with other appropriate agents.
5. Mycobacterial (nontuberculous) infection: M. avium complex (off-label use): 10 to 15 mg/kg once daily or 15 to 25 mg/kg 3 times weekly for first 2 to 3 months as part of an appropriate combination regimen.
6. Nocardiosis, severe (off-label use) : IV: 10 to 15 mg/kg once daily as part of an appropriate combination regimen.
7. Plague (Yersinia pestis), treatment (alternative agent) (off-label use) : IV, IM: 15 to 20 mg/kg once daily for 7 to 14 days and for at least a few days after clinical resolution.
8. Pneumonia, hospital-acquired or ventilator-associated (alternative agent) : IV: 15 to 20 mg/kg once daily in combination with a second gram-negative agent.
9. Sepsis or septic shock, adjunctive empiric gram-negative coverage: IV: 15 to 30 mg/kg once daily in combination with a second gram-negative agent.
10. Tuberculosis, drug resistant (alternative agent) (off-label use) : IM, IV: 15 mg/kg once daily or 25 mg/kg 3 times weekly in combination with additional appropriate antituberculosis agents.

1. CNS infection: IV: 20 to 30 mg/kg/day divided every 8 hours.
2. Cystic fibrosis, acute pulmonary exacerbation: Extended-interval dosing: IV, IM: 30 to 35 mg/kg/dose every 24 hours; Traditional dosing: Infants: IV, IM: 10 mg/kg/dose every 8 hours.
3. Endocarditis, treatment: IV: 15 mg/kg/day divided every 8 to 12 hours.
4. Intra-abdominal infection, complicated: IV: 15 to 22.5 mg/kg/day divided every 8 to 24 hours.
5. Tuberculosis, active (drug-resistant); treatment (alternative agent) : IM, IV: 15 to 20 mg/kg/dose every 24 hours.
6. Peritonitis (CAPD) : Intraperitoneal: Continuous: Loading dose: 25 mg per liter of dialysate; maintenance dose: 12 mg per liter.

GFR 30 to 50 mL/minute/1.73 m2: 5 to 7.5 mg/kg/dose every 12 to 18 hours.
GFR 10 to 29 mL/minute/1.73 m2: 5 to 7.5 mg/kg/dose every 18 to 24 hours.
GFR <10 mL/minute/1.73 m2: 5 to 7.5 mg/kg/dose every 48 to 72 hours.
Intermittent hemodialysis: 5 mg/kg/dose; redose as indicated by serum concentrations.
Peritoneal dialysis (PD): 5 mg/kg/dose; redose as indicated by serum concentrations.
Continuous renal replacement therapy (CRRT): 7.5 mg/kg/dose every 12 hours, monitor serum concentrations.